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Background: Blood biomarkers are increasingly used to diagnose, guide therapy in, and risk-stratify community-
acquired pneumonia (CAP) patients in emergency departments (EDs). How pre-analytic factors affect these markers’
initial levels in this population is unknown.
Methods: In this secondary analysis of consecutive ED patients with CAP from a large multicentre antibiotic
stewardship trial, we used adjusted multivariate regression models to determine the magnitude and statistical
significance of differences in mean baseline concentrations of five biomarkers (procalcitonin [PCT], C-reactive protein
[CRP], white blood cells count [WBC], proadrenomedullin [ProADM], copeptin) associated with six pre-analytic factors
(antibiotic or corticosteroid pretreatment, age, gender, chronic renal failure or chronic liver insufficiency).
Results: Of 925 CAP patients (median age 73 years, 58.8% male), 25.5% had antibiotic pretreatment, 2.4%,
corticosteroid pretreatment, 22.3%, chronic renal failure, 2.4% chronic liver insufficiency. Differences associated
with pre-analytic factors averaged 6.1% ±4.6%; the three largest statistically significant changes (95% confidence
interval) were: PCT, +14.2% (+2.1% to +26.4%, p = 0.02) with liver insufficiency; ProADM, +13.2% (+10.2% to +16.1%,
p < 0.01) with age above median; CRP, -12.8% (-25.4% to -0.2%, p = 0.05) with steroid pretreatment. In post hoc
sensitivity analyses, reclassification statistics showed that these factors did not result in significant changes of
biomarker levels across clinically used cut-off ranges.
Conclusions: Despite statistically significant associations of some pre-analytic factors and biomarker levels, a
clinically relevant influence seems unlikely. Our observations reinforce the concept of using biomarkers in algorithms
with widely-separated cut-offs and overruling criteria considering the entire clinical picture.
Trial registration: Identifier ISRCTN95122877.
Keywords: Community-acquired pneumonia, Blood biomarkers, Procalcitonin, C-reactive protein, White blood cells
count, Proadrenomedullin, Copeptin, Pre-analytic factors, PretreatmentBackground
To improve outcomes in community-acquired pneumonia
(CAP), management guidelines emphasize early diagnosis
to enable a timely start of appropriate antimicrobial ther-
apy [1,2]. For this purpose, circulating levels of biomarkers
associated with bacterial infection and inflammation, pro-
calcitonin (PCT), as well as C-reactive protein (CRP) and
white blood cells count (WBC), are increasingly consid-
ered in the initial assessment of patients with signs or* Correspondence: schuetzph@gmail.com
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unless otherwise stated.symptoms suggestive of CAP [3-5]. Additionally, bio-
markers mirroring disease-related stress, physiological
reserve, or both, are more often being used to stratify
disease severity and risk of patients with CAP, to aid in
triage and in site-of-care decision-making [6-9]. These
analytes include proadrenomedullin (ProADM) or copep-
tin, which are stoichiometrically co-secreted with adreno-
medullin or vasopressin, respectively.
Before admission, CAP patients presenting to the emer-
gency department (ED) frequently have received pretreat-
ment with antibiotics or corticosteroids. Further, these
patients are often elderly and may have varying degrees of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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conceivably could affect initial biomarker levels and
hence confound assay interpretation or require adjust-
ment in analysing cut-offs. For example, hepatocyte
malfunction affects the main site of CRP synthesis,
renal failure could lead to accumulation of proteins
normally excreted in the urine, and elderly patients
might have a suppressed inflammatory response [10].
The presence and magnitude of any differences in con-
centrations of newer biomarkers that may be associated
with pre-analytic factors in patients with CAP is import-
ant [11-17]. Previous literature has addressed such associ-
ations only in healthy volunteers or critical care patients,
populations differing greatly from ED patients with CAP
in pretreatment, age, gender composition, comorbidity,
and general state [12-14,18].
We therefore sought to characterise in a large, repre-
sentative, and well-defined CAP cohort the relative dif-
ferences in initial levels of five widely used diagnostic or
prognostic blood biomarkers that were associated with
each of six common and potentially important pre-
analytic factors. We hypothesised that the magnitude
and statistical significance of any changes would reflect
the clinical relevance of the relationships and the pos-
sible need to consider adjusted cut-offs in subgroups in
everyday practice. The five blood biomarkers investi-
gated were PCT, CRP, WBC, ProADM, and copeptin,
and the six pre-analytic factors were antibiotic or steroid




This secondary analysis included all patients with con-
firmed CAP from the completed prospective, multicentre,
randomised, controlled ProHOSP study [19]. ProHOSP
assessed PCT-guided antibiotic stewardship in consecutive
adults (age ≥18 years) with presumed lower respiratory in-
fection of <28 days’ duration presenting to EDs at any of
six Swiss secondary or tertiary care, academic or non-
academic hospitals from October 2006 to March 2008 [20].
Patients had to have come from the community or a
nursing home with at least one symptom of cough, spu-
tum production, dyspnoea, tachypnoea, or pleuritic pain,
plus rales during auscultation or at least one infectious
sign (core body temperature >38.0°C, shivering, WBC >10
or <4 cells × 109/L). CAP was confirmed in all patients by
new or increasing radiographic lung infiltrate. Patients
were excluded for active intravenous drug abuse, severe
immunosuppression other than corticosteroids, immi-
nently life-threatening comorbidity, hospital-acquired
pneumonia, or ongoing chronic antibiotic administration.
Short-term antibiotic therapy or corticosteroid treatment
before presentation did not affect eligibility. Withinthe trial, patients were stratified by study center and
randomised 1:1 to antibiotic administration according
to either i) state-of-the-art evidence-based guidelines
(controls) or ii) an algorithm recommending antibiotics
only when PCT values exceeded previously validated
cut-offs [20].
Data on demographics, comorbidities, laboratory and
vital parameters, imaging, current and recent medica-
tion, and other baseline characteristics were assembled
for each patient upon presentation. Antibiotic or steroid
pretreatment and comorbidities were identified through
one or more of patient self-report, general practitioner
notes and medical chart review. We did not collect
data on diagnostic procedures such as CT scans per-
formed during the trial, as such exams took place at
the discretion of the treating physicians rather than
systematically.
Approval for ProHOSP was obtained from all local
ethical committees; patients gave written informed
consent. ProHOSP was registered in the “Current Con-
trolled Trials Database” (http://www.controlled-trials.
com/ISRCTN95122877).
Biomarker measurement
In all patients, blood specimens for later marker measure-
ment were collected upon admission, i.e., within the first
24 hours post-presentation. CRP concentrations were
determined by an enzyme immunoassay (EMIT, Merck
Diagnostica, Zürich, Switzerland) having a <5 mg/L detec-
tion limit. PCT determinations were made using a time-
resolved amplified cryptate emission technology-based
assay (Kryptor® PCT, Thermo Scientific Biomarkers [B R
A H M S AG], Hennigsdorf, Germany) with a 0.06 μg/L
functional sensitivity [21]. ProADM and copeptin were
batch-measured in plasma with sandwich immunoassays
(Kryptor®, Thermo Scientific Biomarkers) with 0.08 nmol/
L and 0.4 pmol/L analytical detection limits, respectively
[15-17,22].
Statistics
Our primary analysis used linear regression models to
investigate the association of each studied pre-analytic
factor with the level of each studied biomarker at ED
presentation. Due to non-linearity, biomarker values were
transformed into deciles before entry into the models. Re-
gression coefficients thus correspond to a decile increase
or decrease.
To investigate the potential influence of antibiotic
pretreatment on biomarker concentrations, we com-
pared the patients who at ED presentation, had any re-
cent antibiotic exposure, regardless of agent(s), dose(s)
or administration route(s), versus the patients without
such exposure. For our analysis of the potential impact
of corticosteroid pretreatment on biomarker levels, we
Table 1 Baseline characteristics of the study sample
Characteristics All patients (N = 925)
Demographic characteristics
Age, median (IQR), yr. 73 (59-82)
Male, % (n) 58.8% (544)
Coexisting illnesses, % (n)a
Chronic renal failure 22.3% (206)
Chronic liver insufficiency 2.4% (22)
Chronic obstructive pulmonary disease 30.5% (282)
Diabetes mellitus 17.5% (162)
Congestive heart failure 17.2% (159)
Clinical history, % (n)
Antibiotic pretreatmenta,b 25.5% (236)












Confusion, % (n) 8.0% (74)
Rales during auscultation, % (n) 68.8% (636)
Pneumonia severity index, median (IQR)c 92 (68-116)
Respiratory rate, median (IQR), breaths/min 20 (16-25)
Systolic blood pressure, median (IQR), mmHg 132 (119-148)
Diastolic blood pressure, median (IQR), mmHg 74 (65-83)
Heart rate, median (IQR), beats/min 95 (82-108)
Body temperature, median (IQR), °C 38.1 (37.2-38.9)
Initial laboratory findings, median (IQR)
PCT, μg/L 0.46 (0.15-2.66)
C-reactive protein, mg/dL 155 (75-252)
White blood cells count, cells × 109/L 12.1 (9-16.4)
ProADM, nmol/L 1.2 (0.81-1.86)
Copeptin, pmol/L 25 (12.7-51.1)
Creatinine, μmol/L 89 (69-113)
Treatment site, % (n)
Inpatient 91.2% (844)
IQR, interquartile range; PCT, procalcitonin; ProADM, proadrenomedullin.
Due to inclusion criteria for the present analysis, all patients had a history of CAP.
aAll data on comorbidities and pretreatments were based on patient report
and medical chart review.
bIncludes patients receiving at least one dose of antibiotics irrespective of
agent, regimen or administration route.
cThe pneumonia severity index [24] is scored based on 20 sociodemographic,
clinical, laboratory, or comorbidity variables. Patients are categorised into 5 classes,
with increasing scores and classes denoting worse severity and mortality risk.
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prednisolone equivalent/day before presentation versus
patients without such treatment. This threshold was
chosen considering dose levels found to be relevant in
prior studies focusing on corticosteroid influence on
biomarker release [14,23]. To analyse the influence of
age, we formed two groups by dichotomising patients ac-
cording to the median age of the study sample, 73 years.
Since the ProHOSP protocol did not call for routine com-
prehensive evaluation of kidney or liver function at pres-
entation, patients were dichotomised as to whether or not
their medical records noted chronic renal failure or
chronic liver insufficiency.
Regression models were adjusted for the following
covariates: pneumonia severity index (PSI) [24], creatinine
(transformed into deciles due to non-linearity), presence of
chronic obstructive pulmonary disease (COPD), and pres-
ence of diabetes mellitus. The PSI is a well-validated CAP
severity/risk scoring system based on a total of 20 sociode-
mographic variables, comorbidities (neoplasia, congestive
heart failure, and hepatic, cerebrovascular or renal disease),
and physical, radiographic, and laboratory findings (not in-
cluding any of our studied biomarkers). Incorporating PSI
as a covariate therefore adjusted for the patient’s CAP
severity and simultaneously, comorbidity and general
state. However, to prevent over-adjustment, for the
analyses regarding the associations of the respective
factors and biomarker levels, we used PSI scores ex-
cluding points for age, gender, or renal or hepatic
dysfunction-related variables.
We also conducted exploratory analyses examining the
influence of each of the six factors of interest on each
of the five biomarker concentrations during a 1-week
follow-up (day 0 [presentation], 3, 5, and 7 values);
methodology is described elsewhere (see Additional file 1).
To evaluate the clinical impact of biomarker level changes,
in post hoc sensitivity analyses, reclassification statistics
were performed (see Additional file 2).
All confidence intervals (CIs) are two-sided; tests were
carried out at 5% significance levels. Analyses were per-
formed with STATA 12.1 (Stata Corp., College Station, TX,
USA). Discrete variables are expressed as counts, percent-
ages, or both, and continuous variables are expressed as me-
dians and interquartile ranges (IQRs; 25th-75th percentiles).
Results
The study sample comprised all 925 confirmed CAP pa-
tients included in the ProHOSP trial. Baseline characteris-
tics are summarised in Table 1. Antibiotic pretreatment
was common, administered to just over one-quarter of the
study sample, whilst steroid pretreatment was uncommon
(2.4% of patients). Typical of the ED population with CAP,
the study sample tended to be elderly and male and had a
substantial comorbidity burden, which included chronic
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liver failure in relatively few patients (2.4%).
Figures 1 and 2 represent graphically, whilst Table 2
lists, adjusted relative differences in initial biomarker
concentrations between subgroups with or without the
studied pre-analytic factors, and the 95% CI of those
differences.PCT
Adjusted relative differences in mean baseline PCT be-
tween those with the studied pre-analytic factors versus
those without those factors ranged from -5.5% (antibiotic
pretreatment) to 14.2% (chronic liver insufficiency). Older
age showed the smallest impact on PCT levels (-0.5%).
Three factors were associated with a significantly differentFigure 1 Forest plots of mean relative differences (%) in initial inf
pretreatment, demographics, or comorbidity: (A) PCT, (B) CRP, (C
protein; WBC, white blood cells count; error bars are 95% CIs. Values o
differences in bold text.initial mean PCT concentration: antibiotic pretreatment
or being male with lower values, and chronic liver insuffi-
ciency with a higher value (Figure 1A).CRP
For average initial CRP, adjusted relative differences
between patients with the studied pre-analytic factors
versus their counterparts without these factors ranged
from -12.8% (steroid pretreatment) to 6.2% (chronic
liver insufficiency). Almost no difference was seen in
patients with chronic renal failure (-0.6%). The differ-
ences in mean baseline CRP were statistically signifi-
cant for three factors: pretreatment with steroids, older
age, or male gender-all were associated with lower
levels (Figure 1B).lammatory biomarker levels at presentation depending on
) WBC. PCT, procalcitonin; CI, confidence interval; CRP, C-reactive
f the differences are given in the right-hand column, with significant
Figure 2 Forest plots of mean relative differences (%) in initial stress/physiologic reserve biomarker levels at presentation depending
on pretreatment, demographics, or comorbidity: (A) ProADM, (B) copeptin. CI, confidence interval; ProADM, proadrenomedullin; error bars
are 95% CIs. Values of the differences are given in the right-hand column, with significant differences in bold text.
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Adjusted differences in initial WBC associated with the
studied pre-analytical factors varied between -4.1% (anti-
biotic pretreatment) to 13.0% (chronic liver insufficiency).
The smallest difference observed was for male gender
(-1.0%). Chronic liver failure was associated with signifi-
cantly elevated mean initial leukocyte count; WBC tended
to be lower in patients receiving prior antibiotics andTable 2 Adjusted percentage relative change (95% CI), initial








(n = 236)a,b (n = 22)a,c (n = 462)
PCT -5.5% (-9.6%,





CRP 1.3% (-3.0%, 5.6%),
p = 0.55
-12.8% (-25.4%,
-0.2%), p = 0.05
-10.7% (-14.6%
-6.9%), p < 0.0











16.1%), p < 0.0






CI, confidence interval; CRP, C-reactive protein; PCT, procalcitonin; WBC, white blood
Values for baseline factors associated with a statistically significant adjusted relative
aAll data on comorbidities and pretreatments were based on patient report and me
bIncludes patients receiving at least one dose of antibiotics irrespective of agent, re
c≥ 20 mg/d prednisolone equivalent.higher in those given prior corticosteroids than in those
not administered the respective pretreatment (Figure 1C).
ProADM
The minimum difference in initial ProADM associated
with the studied pre-analytic factors was 1.8% (steroid
pretreatment) and the maximum was 13.2% (older age).
Differences were significant for five of six studied factorsbiomarker concentrations for selected baseline
dy
n




(n = 544) (n = 206)a (n = 22)a























-5.9%), p < 0.01
10.8% (6.6%,
14.8%), p < 0.01
10.4% (0.5%,
20.2%), p = 0.04)






cells count; ProADM, proadrenomedullin.
change in the initial biomarker level are in bold type.
dical chart review.
gimen, or administration route.
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associated with lower mean ProADM at presentation,
whilst increasing age, chronic renal failure, or chronic
liver insufficiency were associated with higher ProADM
concentrations at that time.Copeptin
Changes in baseline copeptin levels associated with the
studied factors ranged from -2.9% (antibiotic pretreat-
ment) to 12.1% (older age). Male gender showed the
smallest effect (-0.1%). The changes attained statistical
significance for two factors, increasing age and chronic
renal failure, both of which were associated with copep-
tin elevations (Figure 2B).Discussion
The most important and reassuring finding of this sec-
ondary analysis was that, despite statistical significance
of some associations, none of the six studied pre-
analytic factors individually seemed to be linked to dra-
matic relative changes in mean initial levels of any of the
five studied biomarkers. The relative differences in base-
line biomarker concentration between patients with ver-
sus without the factors were statistically significant in
14/30 cases. However, irrespective of whether patients
with the pre-analytic factors had elevated or decreased
biomarker levels, the 30 differences themselves ranged
from 0.1% to 14.2% and averaged 6.1% ±4.6% (9.5% ±3.5%
for the 14 significant differences), and even their 95% CIs
never included a >27% change.
These observations support the current concept of
using blood biomarkers in validated algorithms with a
few widely separated cut-offs, without formal adjustment
for pre-analytic factors [4,6]. At least regarding antibiotic
stewardship in CAP, this concept has proved clearly suc-
cessful. For example, PCT algorithms developed in clin-
ical trials to recommend or strongly recommend for/
against starting antibiotics in patients presenting to the
ED with presumed CAP generally applied PCT cut-offs
of 0.1 μg/L, 0.25 μg/L, and 0.5 μg/L [6]; a proposed algo-
rithm for CAP severity/risk classification using ProADM
plus a clinical scoring system contains ProADM cut-offs
of 0.75 nmol/L and 1.5 nmol/L [8,25]. Where higher-risk
or higher-severity clinical categories are delineated by a
doubling or more in biomarker concentrations, changes
of 4.1% or even 26.4% (the range in magnitude of signifi-
cant differences and their 95% CIs) that may be associ-
ated with an individual pre-analytic factor would seem
unlikely to produce clinically relevant confounding. This
assumption was further evidenced in post-hoc sensitivity
analyses, namely reclassification analyses, using different
biomarker specific cut-off ranges and estimates from the
above-mentioned models (see Additional file 2).At the same time, our present observations support
the concept that biomarker values should not be used in
isolation. Rather, these values should be considered in
conjunction with the patient’s clinical presentation and
history, imaging and other laboratory results, etc., as well
as in light of the physician’s clinical experience and judg-
ment. One way that present biomarker algorithms ac-
knowledge this concept is by including “overruling
criteria”, i.e., provision to override on a variety of clin-
ical, patient psychosocial, or logistical grounds recom-
mendations based strictly, or largely, on analytic levels
[6,8]. The overruling criteria could provide a “safety net”
in patients presenting with a number of pre-analytic fac-
tors that in aggregate, if not individually, might materi-
ally affect biomarker levels.
Our results are generally in line with previous observa-
tions. For example, Krüger et al. noted lower levels of
PCT and WBC but not of CRP in patients with anti-
biotic pretreatment [11]. Schaaf et al. found slightly de-
creased admission CRP levels in patients with prior
antimicrobial therapy [26]. In our analysis, this associ-
ation only became significant when considering CRP
values during follow-up (see Additional files 1 and 3),
perhaps due at least partly to the delayed kinetics of
CRP versus PCT. Importantly, the Schaaf study was not
adjusted for confounders other than antibiotic pretreat-
ment, which also may help to explain differences with
our results. Similar to our observations, two intensive
care unit studies found decreased CRP levels after meth-
ylprednisolone treatment, reflecting the suppressive ef-
fect of corticosteroids on inflammatory markers [12,13].
Remarkably, no such effects on PCT were observed in
our study or other studies [12,14]. Additionally, Bruns
and colleagues found an influence of inadequate anti-
biotic treatment on CRP levels [27]. Because in our
cohort, we only had an 8% rate of positive blood cul-
tures, with very few multi-resistant bacteria [28], we
were unable to examine this factor.
In older patients, our analysis revealed significantly
lower mean initial CRP levels. This finding might be ex-
plained by the inverse correlation of inflammatory re-
sponse and age [10,29].
Renal clearance is one of the PCT elimination path-
ways [30]. However, the lack of significant change in our
investigated inflammatory biomarker levels in patients
with chronic renal failure also agrees with earlier results
[30-33]. Those data showed that urinary PCT levels were
significantly reduced in patients with severe renal dys-
function. However, despite decreased renal elimination,
the plasma PCT clearance rate correlated only weakly
with renal dysfunction, and thus interpretation of plasma
PCT levels should not be confounded by this condition.
In patients with chronic liver insufficiency, we found sig-
nificantly elevated PCT levels. Similarly, Elefsiniotis et al.
Kutz et al. BMC Anesthesiology 2014, 14:102 Page 7 of 9
http://www.biomedcentral.com/1471-2253/14/102noted that significant proportions of patients with acute al-
coholic hepatitis on a cirrhotic background or with acute
on chronic viral hepatitis but without bacterial infection,
exhibited serum PCT levels above 0.5 μg/L [34].
We are aware of several limitations of the present work.
Firstly, this was a secondary analysis of a previous anti-
biotic stewardship trial. Therefore, clinical information
about pretreatments (dose and duration) and comorbidities
were not always systematically collected. Consequently,
our analysis dichotomised patients broadly with respect to
prior antibiotics or corticosteroids, without considering the
type or regimen of these pretreatments. Nevertheless,
although data on indications for these modalities were
not formally collected, our clinical impression was that
antibiotic pretreatment seemed almost always to have
represented attempts by general practitioners to ad-
dress the respiratory infections eventually precipitating
the ED visits. Additionally, steroid pretreatment seemed
to have been given primarily as therapy for pre-existing
COPD. Another disadvantage of the secondary analysis
was that chronic renal failure and chronic liver insuffi-
ciency were not classified by severity, duration, or
aetiology. All these factors may have led to patient
misclassification. Additionally, given these limitations
to a “pristine” analysis, we did not correct for mul-
tiple comparisons or adjust for potential interactions
between or among studied pre-analytic factors. Ra-
ther, we sought to detect material changes in baseline
concentrations of widely used biomarkers associated
with key pre-analytic factors whilst adjusting for import-
ant potential confounders, namely pneumonia severity
and comorbidity. Therefore, synergistic or compensating
effects of multiple pre-analytic factors in a given patient
cannot be completely excluded based on our results.
Secondly, numbers of patients with prior corticoster-
oid treatment or chronic liver insufficiency were small
(n = 22/925 each), leading to potential under-powering
of related analyses. Nonetheless, we consistently observed
a stable trend of biomarker values in these subgroups dur-
ing the 1-week follow-up, a finding that appears to render
random fluctuation rather unlikely (see Additional files 1,
3 and 4).
Conclusion
Each studied pre-analytic factor appeared to be associ-
ated with a statistically significant relative change in
mean baseline levels of one or more of the examined
biomarkers. However, such changes averaged only 6.1%
overall and 9.5% when statistically significant, and never
exceeded 15%, or, with respect to the outer bounds of
the 95% CIs, 27%. Our findings therefore provide re-
assurance that adjustment for antibiotic or corticosteroid
pretreatment, older age, male gender, or chronic renal
failure or liver insufficiency are in most cases unlikely tobe necessary when biomarkers are used in algorithms
containing a few widely separated cut-offs as well as
overruling criteria allowing consideration of the entire
clinical picture.
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